RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+10.96%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$783M
AUM Growth
+$783M
(+12%)
Cap. Flow
+$41.9M
Cap. Flow
% of AUM
5.35%
Top 10 Holdings %
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$14.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$12.9M |
| 3 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.6M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$10.1M |
| 5 |
Glaukos
GKOS
|
$9.98M |
Top Sells
| 1 |
Pfizer
PFE
|
$15M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$13.8M |
| 3 |
Zimmer Biomet
ZBH
|
$11.6M |
| 4 |
NovoCure
NVCR
|
$10.9M |
| 5 |
Biogen
BIIB
|
$8.3M |
Sector Composition
| 1 | Healthcare | 89.3% |
| 2 | Financials | 1.39% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.13% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Elevance Health
ELV
$72.4B
| $10.4M | 1.33% |
55,000
+28,532
| +108% | +$5.42M |
|
27
Cigna
CI
$80.2B
| $10.3M | 1.31% |
55,000
+10,000
| +22% | +$1.87M |
|
28
Bristol-Myers Squibb
BMY
$96.7B
| $10.2M | 1.31% |
160,502
+46,907
| +41% | +$2.99M |
|
29
Humana
HUM
$37.5B
| $9.99M | 1.28% |
41,000
+6,000
| +17% | +$1.46M |
|
|
AET
30
DELISTED
Aetna Inc
AET
| $9.86M | 1.26% |
62,000
+25,000
| +68% | +$3.98M |
|
31
Regeneron Pharmaceuticals
REGN
$59.8B
| $9.84M | 1.26% |
22,000
+6,900
| +46% | +$3.09M |
|
32
CVS Health
CVS
$93B
| $9.76M | 1.25% |
120,000
+35,000
| +41% | +$2.85M |
|
33
Eli Lilly
LLY
$661B
| $9.41M | 1.2% |
110,000
-40,000
| -27% | -$3.42M |
|
34
Edwards Lifesciences
EW
$47.7B
| $8.75M | 1.12% |
80,000
+47,000
| +142% | +$5.14M |
|
35
Abbott
ABT
$230B
| $8.27M | 1.06% |
155,000
+60,000
| +63% | +$3.2M |
|
36
Boston Scientific
BSX
$159B
| $8.18M | 1.04% |
+280,468
| New | +$8.18M |
|
37
Dynavax Technologies
DVAX
$1.19B
| $8.05M | 1.03% |
374,537
-212,793
| -36% | -$4.58M |
|
|
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
| $8M | 1.02% |
650,000
+225,000
| +53% | +$2.77M |
|
39
FibroGen
FGEN
$48.4M
| $7.83M | 1% |
145,500
-8,841
| -6% | -$476K |
|
40
Alkermes
ALKS
$4.95B
| $7.37M | 0.94% |
145,000
+9,591
| +7% | +$488K |
|
41
Neurocrine Biosciences
NBIX
$13.5B
| $7.05M | 0.9% |
115,000
-5,000
| -4% | -$306K |
|
|
IMMU
42
DELISTED
Immunomedics Inc
IMMU
| $6.99M | 0.89% |
500,000
-29,610
| -6% | -$414K |
|
|
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
| $6.91M | 0.88% |
+75,000
| New | +$6.91M |
|
|
44
Biogen
BIIB
$20.8B
| $6.89M | 0.88% |
22,000
-26,500
| -55% | -$8.3M |
|
|
RVNC
45
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.79M | 0.87% |
246,400
+26,400
| +12% | +$727K |
|
|
ELGX
46
DELISTED
Endologix Inc
ELGX
| $6.66M | 0.85% |
1,492,600
-82,400
| -5% | -$368K |
|
47
LivaNova
LIVN
$3.09B
| $6.66M | 0.85% |
95,000
-6,854
| -7% | -$480K |
|
48
Cencora
COR
$57.2B
| $6.62M | 0.85% |
80,000
+35,000
| +78% | +$2.9M |
|
49
Sanofi
SNY
$122B
| $6.47M | 0.83% |
130,000
-30,000
| -19% | -$1.49M |
|
|
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $6.47M | 0.83% |
+150,872
| New | +$6.47M |
|